Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
39.041,36 -28,32 (-0,07%) EUR/USD
1,0862 +0,0001 (+0,01%) Bitcoin EUR
65.249,45 +3.389,07 (+5,48%) CMC Crypto 200
1.526,18 +171,77 (+12,68%)
Minerva Neurosciences, Inc. (4MNA.F)
| Chiusura precedente | 2,2600 |
| Aperto | 2,2200 |
| Denaro | 2,2000 x N/D |
| Lettera | 2,3600 x N/D |
| Min-Max giorno | 2,2200 - 2,2200 |
| Intervallo di 52 settimane | 2,0800 - 11,6300 |
| Volume | |
| Media Volume | 66 |
| Capitalizzazione | 15,951M |
| Beta (5 anni mensile) | 0,26 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,0700 |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireMinerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second quarter ended June 30, 2023. “In the second quarter, we completed an equity financing of $20.0 million, further strengthening our cash position. This investment from Boehringer Ingelheim and Federated Hermes
- GlobeNewswire
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, to B
